Hyperthyroidism.
Graves’ disease (GD)
Hyperthyroidism
radioactive iodine (RAI)
surgery
toxic adenoma
toxic multinodular goiter
Journal
Gland surgery
ISSN: 2227-684X
Titre abrégé: Gland Surg
Pays: China (Republic : 1949- )
ID NLM: 101606638
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
entrez:
25
3
2020
pubmed:
25
3
2020
medline:
25
3
2020
Statut:
ppublish
Résumé
Hyperthyroidism is a condition where the thyroid gland produces and secretes inappropriately high amounts of thyroid hormone which can lead to thyrotoxicosis. The prevalence of hyperthyroidism in the United States is approximately 1.2%. There are many different causes of hyperthyroidism, and the most common causes include Graves' disease (GD), toxic multinodular goiter and toxic adenoma. The diagnosis can be made based on clinical findings and confirmed with biochemical tests and imaging techniques including ultrasound and radioactive iodine uptake scans. This condition impacts many different systems of the body including the integument, musculoskeletal, immune, ophthalmic, reproductive, gastrointestinal and cardiovascular systems. It is important to recognize common cardiovascular manifestations such as hypertension and tachycardia and to treat these patients with beta blockers. Early treatment of cardiovascular manifestations along with treatment of the hyperthyroidism can prevent significant cardiovascular events. Management options for hyperthyroidism include anti-thyroid medications, radioactive iodine, and surgery. Anti-thyroid medications are often used temporarily to treat thyrotoxicosis in preparation for more definitive treatment with radioactive iodine or surgery, but in select cases, patients can remain on antithyroid medications long-term. Radioactive iodine is a successful treatment for hyperthyroidism but should not be used in GD with ophthalmic manifestations. Recent studies have shown an increased concern for the development of secondary cancers as a result of radioactive iodine treatment. In the small percentage of patients who are not successfully treated with radioactive iodine, they can undergo re-treatment or surgery. Surgery includes a total thyroidectomy for GD and toxic multinodular goiters and a thyroid lobectomy for toxic adenomas. Surgery should be considered for those who have a concurrent cancer, in pregnancy, for compressive symptoms and in GD with ophthalmic manifestations. Surgery is cost effective with a high-volume surgeon. Preoperatively, patients should be on anti-thyroid medications to establish a euthyroid state and on beta blockers for any cardiovascular manifestations. Thyroid storm is a rare but life-threatening condition that can occur with thyrotoxicosis that must be treated with a multidisciplinary approach and ultimately, definitive treatment of the hyperthyroidism.
Identifiants
pubmed: 32206604
doi: 10.21037/gs.2019.11.01
pii: gs-09-01-124
pmc: PMC7082267
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
124-135Informations de copyright
2020 Gland Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Front Endocrinol (Lausanne). 2019 Jul 17;10:482
pubmed: 31379748
Thyroid. 2014 Dec;24(12):1759-64
pubmed: 25268754
J Community Hosp Intern Med Perspect. 2016 Sep 07;6(4):31750
pubmed: 27609719
Thyroid. 2019 Mar;29(3):332-340
pubmed: 30648498
J Clin Endocrinol Metab. 2001 Jul;86(7):3016-21
pubmed: 11443161
N Engl J Med. 1992 Jun 25;326(26):1733-8
pubmed: 1489388
Eur J Endocrinol. 2005 May;152(5):695-701
pubmed: 15879354
Eur J Endocrinol. 2005 Oct;153(4):489-98
pubmed: 16189168
Endocr Res. 2015;40(1):25-8
pubmed: 24833206
Int J Surg. 2016 Mar;27:118-25
pubmed: 26626367
J Surg Res. 2019 Dec;244:102-106
pubmed: 31279993
Eur J Endocrinol. 2018 Oct 12;179(5):R261-R274
pubmed: 30320502
Br J Surg. 2014 Mar;101(4):307-20
pubmed: 24402815
Clin Endocrinol (Oxf). 2011 May;74(5):636-43
pubmed: 21470287
World J Surg. 2008 Jul;32(7):1278-84
pubmed: 18357484
J Am Coll Surg. 2016 Jan;222(1):83-8
pubmed: 26584573
Heart. 2007 Apr;93(4):483-7
pubmed: 17005710
Am J Manag Care. 2012 Jan 01;18(1):e1-14
pubmed: 22435785
J Ultrasound Med. 2013 Mar;32(3):505-11
pubmed: 23443191
Horm Metab Res. 2004 Feb;36(2):92-6
pubmed: 15002058
Am J Med. 1990 Jun;88(6):642-6
pubmed: 2189309
J Natl Cancer Inst. 2015 Nov 03;108(2):
pubmed: 26538627
J Am Heart Assoc. 2012 Aug;1(4):e001081
pubmed: 23130158
Ann Surg Oncol. 2014 Nov;21(12):3844-52
pubmed: 24943236
Surgery. 2017 Jan;161(1):289-296
pubmed: 27866719
J Clin Endocrinol Metab. 1974 Jun;38(6):976-98
pubmed: 4134013
Am J Med. 1982 Dec;73(6):867-71
pubmed: 6816067
J Clin Endocrinol Metab. 2015 Oct;100(10):3710-7
pubmed: 26262435
N Engl J Med. 2011 Feb 10;364(6):542-50
pubmed: 21306240
Thyroid. 2005 Sep;15(9):1047-54
pubmed: 16187913
Eur J Endocrinol. 2009 Nov;161(5):771-7
pubmed: 19671708
Curr Probl Cardiol. 2016 Feb;41(2):65-92
pubmed: 26792255
Trends Cardiovasc Med. 2020 Feb;30(2):57-69
pubmed: 30871865
J Clin Endocrinol Metab. 1982 Jan;54(1):101-7
pubmed: 6274892
J Endocrinol Invest. 1983 Dec;6(6):493-505
pubmed: 6368663
Clin Endocrinol (Oxf). 2007 Jul;67(1):41-5
pubmed: 17437515
Arch Intern Med. 1989 Mar;149(3):526-32
pubmed: 2493228
Ann Surg Oncol. 2014 Dec;21(13):4174-80
pubmed: 25001092
Surgery. 2013 Dec;154(6):1346-52; discussion 1352-3
pubmed: 24238052
Ann Surg Oncol. 2015 Apr;22(4):1196-9
pubmed: 25245130
Am J Med. 1990 Nov;89(5):602-8
pubmed: 2239979
Curr Hypertens Rep. 2003 Dec;5(6):513-20
pubmed: 14594573
J Clin Endocrinol Metab. 2007 Jun;92(6):2157-62
pubmed: 17389704
Endocrinol Metab Clin North Am. 1993 Jun;22(2):263-77
pubmed: 8325286
J Clin Med Res. 2019 May;11(5):383-384
pubmed: 31019634
Ann Surg Oncol. 2014 Jul;21(7):2303-9
pubmed: 24522995
Thyroid. 2012 Jul;22(7):661-79
pubmed: 22690898
J Clin Hypertens (Greenwich). 2006 Aug;8(8):596-9
pubmed: 16896276
Cancer. 2007 May 15;109(10):1972-9
pubmed: 17393376
J Clin Endocrinol Metab. 2009 Jun;94(6):1853-78
pubmed: 19494161
Mol Cell Endocrinol. 2010 Jun 30;322(1-2):125-34
pubmed: 20138963
N Engl J Med. 2010 Feb 25;362(8):726-38
pubmed: 20181974
J Clin Endocrinol Metab. 1987 Oct;65(4):719-23
pubmed: 3654917
J Clin Endocrinol Metab. 2015 Feb;100(2):451-9
pubmed: 25343237
Case Rep Endocrinol. 2018 Jan 2;2018:4190629
pubmed: 29487752
J Endocrinol Invest. 2006 Jul-Aug;29(7):594-8
pubmed: 16957406
Acta Endocrinol (Copenh). 1980 Jan;93(1):32-6
pubmed: 7355663
Endocrinol Metab Clin North Am. 2014 Jun;43(2):517-28
pubmed: 24891175
Perm J. 2019;23:
pubmed: 31167702
Thyroid. 2016 Oct;26(10):1343-1421
pubmed: 27521067
BMC Res Notes. 2014 Nov 18;7:814
pubmed: 25927843
Thyroid. 2015 Dec;25(12):1282-90
pubmed: 26414885
Ann Endocrinol (Paris). 2011 Sep;72(4):296-303
pubmed: 21777903
Am J Med. 1983 Aug;75(2):353-9
pubmed: 6349350
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
N Engl J Med. 2003 Jun 26;348(26):2646-55
pubmed: 12826640
Lancet. 2016 Aug 27;388(10047):906-918
pubmed: 27038492
Eur J Endocrinol. 2008 Jan;158(1):69-75
pubmed: 18166819
Clin Endocrinol (Oxf). 1988 Mar;28(3):305-14
pubmed: 3168311
Lancet. 1975 Oct 4;2(7936):635-7
pubmed: 52005
JAMA. 1998 Jul 22-29;280(4):347-55
pubmed: 9686552
Eur J Endocrinol. 2004 Jun;150(6):757-62
pubmed: 15191344
Nucl Med Commun. 2019 May;40(5):455-460
pubmed: 30855542
Expert Rev Endocrinol Metab. 2018 May;13(3):137-148
pubmed: 30058897
Ann Surg Oncol. 2015 Mar;22(3):952-8
pubmed: 25212835
J Clin Endocrinol Metab. 1999 Nov;84(11):4012-6
pubmed: 10566642
Endocr J. 2006 Aug;53(4):467-72
pubmed: 16820704
Ann Surg Oncol. 2013 Feb;20(2):660-7
pubmed: 22956065
J Clin Endocrinol Metab. 2010 Jun;95(6):2715-26
pubmed: 20392869
J Clin Endocrinol Metab. 2002 Mar;87(3):1073-7
pubmed: 11889166
Surgery. 2018 Jan;163(1):68-72
pubmed: 29108701
Eur J Endocrinol. 2013 Oct 01;169(5):537-45
pubmed: 23935127
Endocr Relat Cancer. 2012 Sep 14;19(5):645-55
pubmed: 22851687
J Clin Endocrinol Metab. 1975 Nov;41(5):911-20
pubmed: 1242390
JAMA Intern Med. 2019 Jul 1;:
pubmed: 31260066